Reck mentioned the IMpower010 and CheckMate 816 trials investigating treatment options for patients with non-small cell lung cancer.
CancerNetwork® spoke with Martin Reck, MD, PhD, of the Lung Clinic Grosshansdorf, about some compelling data in non–small cell lung cancer presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting that has the potential to alter the treatment paradigm of this disease.
There are some additional data which are of interest. In particular, when we look at nonmetastatic non–small cell lung cancer, we will see the IMpower010 trial [NCT02486718], which is the first trial showing a benefit for an adjuvant treatment with a checkpoint inhibitor. This clearly is an important trial.
And of course, every one of us is very excited to see more details of the CheckMate 816 [NCT02998528], [after] we had seen the first positive results for one of the coprimary end points, pathological response rate, at the AACR Meeting. We also will get additional information about the surgical outcomes of this trial at the ASCO meeting this year. I think in general, moving to nonmetastatic non–small cell lung cancer will be a very important practice [with] relevant developments of immunotherapies.